Loop Diuretics in Heart Failure: Torsemide and furosemide equally effective regardless of HF type
A recent post hoc analysis of the TRANSFORM-HF trial explored the clinical profiles and outcomes of heart failure (HF) patients treated with torsemide versus furosemide, focusing on differences between de novo HF and worsening chronic HF (WHF). This study was published in JAMA Cardiology by Selim R. and colleagues.
The study included 2,858 patients with documented ejection fraction, revealing that 838 patients had de novo HF, and 2,020 had WHF. Noteworthy distinctions were observed, with de novo HF patients being younger, having a higher glomerular filtration rate, lower natriuretic peptide levels, and receiving lower doses of loop diuretics compared to WHF patients.
De novo HF was associated with lower all-cause mortality at 12 months (9.1% vs. 25.4% in WHF).
Patients with de novo HF exhibited lower all-cause first rehospitalization rates and greater improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 12 months.
Torsemide and furosemide showed no significant difference in mortality, hospitalization rates, or total hospitalizations at 12 months for both de novo HF and WHF.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.